Papers

Publications automatically retrieved from PubMed (last updated: 2025-09-16)

Lee M, Cullen AE, Matheson GJ, Lu ZA, Bergen SE, Sellgren CM, Erhardt S, Fatouros-Bergman H & Cervenka S (2025). Cognition before and after psychosis onset: A naturalistic study of change, heterogeneity, and prognosis. Schizophr Res Cogn, 42, 100387. PubMed
Matheson GJ, Zanderigo F, Miller JM, Bartlett EA, Mann JJ & Ogden RT (2025). PET imaging of the serotonin 1A receptor in major depressive disorder: Hierarchical multivariate analysis of [ 11 C]WAY100635 overcomes outcome measure discrepancies. Imaging Neurosci (Camb), 2. PubMed
Reed MB, Cocchi L, Sander CY, Chen J, Matheson GJ, Fisher P, Volpi T, Khattar N, DeLorenzo C, Gryglewski G, Silberbauer LR, Murgaš M, Godbersen GM, Nics L, Walter M, Hacker M, Bertoldo A, Lubberink M, Silfstein M, Ogden RT, Mann JJ, Suhara T, Varrone A, Boellaard R, Gunn RN, Hammers A, Biswal B, Rosen B, Knudsen GM, Carson R, Price J, Lanzenberger R & Hahn A (2025). Connecting the dots: approaching a standardized nomenclature for molecular connectivity in positron emission tomography. Eur J Nucl Med Mol Imaging. PubMed
Eierud C, Norgaard M, Bilgel M, Petropoulos H, Fu Z, Iraji A, Matheson GJ, Ganz M, Pernet C & Calhoun VD (2025). Building Multivariate Molecular Imaging Brain Atlases Using the NeuroMark PET Independent Component Analysis Framework. bioRxiv. PubMed
Matheson GJ, Lundberg J, Gärde M, Veldman ER, Tateno A, Okubo Y, Tiger M & Ogden RT (2024). A Reference Tissue Implementation of Simultaneous Multifactor Bayesian Analysis (SiMBA) of PET Time Activity Curve Data. bioRxiv. PubMed
Galassi A, Norgaard M, Thomas AG, Gonzalez-Escamilla G, Svarer C, Rorden C, Matheson GJ, Knudsen GM, Innis RB, Ganz M, Eierud C, Bilgel M & Pernet C (2024). PET2BIDS: a library for converting Positron Emission Tomography data to BIDS. J Open Source Softw, 9(100). PubMed
Gärde M, Matheson GJ, Varnäs K, Svenningsson P, Hedman-Lagerlöf E, Lundberg J, Farde L & Tiger M (2024). Altered Serotonin 1B Receptor Binding After Escitalopram for Depression Is Correlated With Treatment Effect. Int J Neuropsychopharmacol, 27(5). PubMed
Matheson GJ, Zanderigo F, Miller JM, Bartlett EA, Mann JJ & Ogden RT (2024). PET Imaging of the Serotonin 1A Receptor in Major Depressive Disorder: Hierarchical Multivariate Analysis of [11C]WAY100635 Overcomes Outcome Measure Discrepancies. bioRxiv. PubMed
Matheson GJ, Ge L, Zhang M, Sun B, Tu Y, Zanderigo F, Forsberg Morèn A & Ogden RT (2023). Parametric and non-parametric Poisson regression for modelling of the arterial input function in positron emission tomography. EJNMMI Phys, 10(1), 72. PubMed
Shieh D, Matheson GJ & Ogden RT (2023). Nonlinear Mixed-Effects Modeling Approach for Simplified Reference Tissue Model. IEEE Trans Biomed Eng, 71(4), 1191-1196. PubMed
Matheson GJ & Ogden RT (2023). Multivariate analysis of PET pharmacokinetic parameters improves inferential efficiency. EJNMMI Phys, 10(1), 17. PubMed
Jangard S, Jayaram-Lindström N, Isacsson NH, Matheson GJ, Plavén-Sigray P, Franck J, Borg J, Farde L & Cervenka S (2023). Striatal dopamine D2 receptor availability as a predictor of subsequent alcohol use in social drinkers. Addiction, 118(6), 1053-1061. PubMed
Balter LJT, Matheson GJ, Sundelin T, Sterzer P, Petrovic P & Axelsson J (2022). Experimental Sleep Deprivation Results in Diminished Perceptual Stability Independently of Psychosis Proneness. Brain Sci, 12(10). PubMed
Millischer V, Matheson GJ, Bergen SE, Coombes BJ, Ponzer K, Wikström F, Jagiello K, Lundberg M, Stenvinkel P, Biernacka JM, Breuer O, Martinsson L, Landén M, Backlund L, Lavebratt C & Schalling M (2022). Improving lithium dose prediction using population pharmacokinetics and pharmacogenomics: a cohort genome-wide association study in Sweden. Lancet Psychiatry, 9(6), 447-457. PubMed
Matheson GJ & Ogden RT (2022). Simultaneous multifactor Bayesian analysis (SiMBA) of PET time activity curve data. Neuroimage, 256, 119195. PubMed
Norgaard M, Matheson GJ, Hansen HD, Thomas A, Searle G, Rizzo G, Veronese M, Giacomel A, Yaqub M, Tonietto M, Funck T, Gillman A, Boniface H, Routier A, Dalenberg JR, Betthauser T, Feingold F, Markiewicz CJ, Gorgolewski KJ, Blair RW, Appelhoff S, Gau R, Salo T, Niso G, Pernet C, Phillips C, Oostenveld R, Gallezot JD, Carson RE, Knudsen GM, Innis RB & Ganz M (2022). PET-BIDS, an extension to the brain imaging data structure for positron emission tomography. Sci Data, 9(1), 65. PubMed
Plavén-Sigray P, Ikonen Victorsson P, Santillo A, Matheson GJ, Lee M, Collste K, Fatouros-Bergman H, Sellgren CM, Erhardt S, Agartz I, Halldin C, Farde L & Cervenka S (2021). Thalamic dopamine D2-receptor availability in schizophrenia: a study on antipsychotic-naive patients with first-episode psychosis and a meta-analysis. Mol Psychiatry, 27(2), 1233-1240. PubMed
Tiger M, Gärde M, Tateno A, Matheson GJ, Sakayori T, Nogami T, Moriya H, Varnäs K, Arakawa R & Okubo Y (2021). A positron emission tomography study of the serotonin1B receptor effect of electroconvulsive therapy for severe major depressive episodes. J Affect Disord, 294, 645-651. PubMed
Bai W, Al-Karaghouli M, Stach J, Sung S, Matheson GJ & Abraldes JG (2021). Test-Retest Reliability and Consistency of HVPG and Impact on Trial Design: A Study in 289 Patients from 20 Randomized Controlled Trials. Hepatology, 74(6), 3301-3315. PubMed
Freiburghaus T, Svensson JE, Matheson GJ, Plavén-Sigray P, Lundberg J, Farde L & Cervenka S (2020). Low convergent validity of [11C]raclopride binding in extrastriatal brain regions: A PET study of within-subject correlations with [11C]FLB 457. Neuroimage, 226, 117523. PubMed
Kerstens VS, Fazio P, Sundgren M, Matheson GJ, Franzén E, Halldin C, Cervenka S, Svenningsson P & Varrone A (2020). Reliability of dopamine transporter PET measurements with [18F]FE-PE2I in patients with Parkinson’s disease. EJNMMI Res, 10(1), 95. PubMed
Plavén-Sigray P, Matheson GJ, Coughlin JM, Hafizi S, Laurikainen H, Ottoy J, De Picker L, Rusjan P, Hietala J, Howes OD, Mizrahi R, Morrens M, Pomper MG & Cervenka S (2020). Meta-analysis of the Glial Marker TSPO in Psychosis Revisited: Reconciling Inconclusive Findings of Patient-Control Differences. Biol Psychiatry, 89(3), e5-e8. PubMed
Tjerkaski J, Cervenka S, Farde L & Matheson GJ (2020). Kinfitr - an open-source tool for reproducible PET modelling: validation and evaluation of test-retest reliability. EJNMMI Res, 10(1), 77. PubMed
Matheson GJ, Plavén-Sigray P, Louzolo A, Borg J, Farde L, Petrovic P & Cervenka S (2020). Dopamine D1 receptor availability is not associated with delusional ideation measures of psychosis proneness. Schizophr Res, 222, 175-184. PubMed
Knudsen GM, Ganz M, Appelhoff S, Boellaard R, Bormans G, Carson RE, Catana C, Doudet D, Gee AD, Greve DN, Gunn RN, Halldin C, Herscovitch P, Huang H, Keller SH, Lammertsma AA, Lanzenberger R, Liow JS, Lohith TG, Lubberink M, Lyoo CH, Mann JJ, Matheson GJ, Nichols TE, Nørgaard M, Ogden T, Parsey R, Pike VW, Price J, Rizzo G, Rosa-Neto P, Schain M, Scott PJ, Searle G, Slifstein M, Suhara T, Talbot PS, Thomas A, Veronese M, Wong DF, Yaqub M, Zanderigo F, Zoghbi S & Innis RB (2020). Guidelines for the content and format of PET brain data in publications and archives: A consensus paper. J Cereb Blood Flow Metab, 40(8), 1576-1585. PubMed
Millischer V, Matheson GJ, Martinsson L, Römer Ek I, Schalling M, Lavebratt C & Backlund L (2019). AKT1 and genetic vulnerability to bipolar disorder. Psychiatry Res, 284, 112677. PubMed
Matheson GJ, Plavén-Sigray P, Tuisku J, Rinne J, Matuskey D & Cervenka S (2019). Clinical brain PET research must embrace multi-centre collaboration and data sharing or risk its demise. Eur J Nucl Med Mol Imaging, 47(2), 502-504. PubMed
Matheson GJ (2019). We need to talk about reliability: making better use of test-retest studies for study design and interpretation. PeerJ, 7, e6918. PubMed
Stenkrona P, Matheson GJ, Halldin C, Cervenka S & Farde L (2019). D1-Dopamine Receptor Availability in First-Episode Neuroleptic Naive Psychosis Patients. Int J Neuropsychopharmacol, 22(7), 415-425. PubMed
Caravaggio F, Plavén-Sigray P, Matheson GJ, Plitman E, Chakravarty MM, Borg J, Graff-Guerrero A & Cervenka S (2018). Trait impulsivity is not related to post-commissural putamen volumes: A replication study in healthy men. PLoS One, 13(12), e0209584. PubMed
Plavén-Sigray P, Matheson GJ, Cselényi Z, Jucaite A, Farde L & Cervenka S (2018). Test-retest reliability and convergent validity of (R)-[11C]PK11195 outcome measures without arterial input function. EJNMMI Res, 8(1), 102. PubMed
Griffioen G, Matheson GJ, Cervenka S, Farde L & Borg J (2018). Serotonin 5-HT1A receptor binding and self-transcendence in healthy control subjects-a replication study using Bayesian hypothesis testing. PeerJ, 6, e5790. PubMed
Stenkrona P, Matheson GJ, Cervenka S, Sigray PP, Halldin C & Farde L (2018). [11C]SCH23390 binding to the D1-dopamine receptor in the human brain-a comparison of manual and automated methods for image analysis. EJNMMI Res, 8(1), 74. PubMed
Plavén-Sigray P, Matheson GJ, Collste K, Ashok AH, Coughlin JM, Howes OD, Mizrahi R, Pomper MG, Rusjan P, Veronese M, Wang Y & Cervenka S (2018). Positron Emission Tomography Studies of the Glial Cell Marker Translocator Protein in Patients With Psychosis: A Meta-analysis Using Individual Participant Data. Biol Psychiatry, 84(6), 433-442. PubMed
Plavén-Sigray P, Matheson GJ, Gustavsson P, Stenkrona P, Halldin C, Farde L & Cervenka S (2018). Is dopamine D1 receptor availability related to social behavior? A positron emission tomography replication study. PLoS One, 13(3), e0193770. PubMed
Plavén-Sigray P, Matheson GJ, Schiffler BC & Thompson WH (2017). The readability of scientific texts is decreasing over time. Elife, 6. PubMed
Matheson GJ, Plavén-Sigray P, Forsberg A, Varrone A, Farde L & Cervenka S (2017). Assessment of simplified ratio-based approaches for quantification of PET [11C]PBR28 data. EJNMMI Res, 7(1), 58. PubMed
Matheson GJ, Stenkrona P, Cselényi Z, Plavén-Sigray P, Halldin C, Farde L & Cervenka S (2017). Reliability of volumetric and surface-based normalisation and smoothing techniques for PET analysis of the cortex: A test-retest analysis using [11C]SCH-23390. Neuroimage, 155, 344-353. PubMed
Plavén-Sigray P, Hedman E, Victorsson P, Matheson GJ, Forsberg A, Djurfeldt DR, Rück C, Halldin C, Lindefors N & Cervenka S (2017). Extrastriatal dopamine D2-receptor availability in social anxiety disorder. Eur Neuropsychopharmacol, 27(5), 462-469. PubMed
Borg J, Cervenka S, Kuja-Halkola R, Matheson GJ, Jönsson EG, Lichtenstein P, Henningsson S, Ichimiya T, Larsson H, Stenkrona P, Halldin C & Farde L (2016). Contribution of non-genetic factors to dopamine and serotonin receptor availability in the adult human brain. Mol Psychiatry, 21(8), 1077-84. PubMed
Matheson GJ, Schain M, Almeida R, Lundberg J, Cselényi Z, Borg J, Varrone A, Farde L & Cervenka S (2015). Diurnal and seasonal variation of the brain serotonin system in healthy male subjects. Neuroimage, 112, 225-231. PubMed

--- title: "Papers" subtitle: "Academic Publications" date: 2025-09-16 --- *Publications automatically retrieved from PubMed (last updated: 2025-09-16)* ## Papers 1. Lee M, Cullen AE, **Matheson GJ**, Lu ZA, Bergen SE, Sellgren CM, Erhardt S, Fatouros-Bergman H & Cervenka S (2025). Cognition before and after psychosis onset: A naturalistic study of change, heterogeneity, and prognosis. *Schizophr Res Cogn*, *42*, 100387. [PubMed](https://pubmed.ncbi.nlm.nih.gov/40933840) 2. **Matheson GJ**, Zanderigo F, Miller JM, Bartlett EA, Mann JJ & Ogden RT (2025). PET imaging of the serotonin 1A receptor in major depressive disorder: Hierarchical multivariate analysis of [ 11 C]WAY100635 overcomes outcome measure discrepancies. *Imaging Neurosci (Camb)*, *2*. [PubMed](https://pubmed.ncbi.nlm.nih.gov/40800447) 3. Reed MB, Cocchi L, Sander CY, Chen J, **Matheson GJ**, Fisher P, Volpi T, Khattar N, DeLorenzo C, Gryglewski G, Silberbauer LR, Murgaš M, Godbersen GM, Nics L, Walter M, Hacker M, Bertoldo A, Lubberink M, Silfstein M, Ogden RT, Mann JJ, Suhara T, Varrone A, Boellaard R, Gunn RN, Hammers A, Biswal B, Rosen B, Knudsen GM, Carson R, Price J, Lanzenberger R & Hahn A (2025). Connecting the dots: approaching a standardized nomenclature for molecular connectivity in positron emission tomography. *Eur J Nucl Med Mol Imaging*. [PubMed](https://pubmed.ncbi.nlm.nih.gov/40455254) 4. Eierud C, Norgaard M, Bilgel M, Petropoulos H, Fu Z, Iraji A, **Matheson GJ**, Ganz M, Pernet C & Calhoun VD (2025). Building Multivariate Molecular Imaging Brain Atlases Using the NeuroMark PET Independent Component Analysis Framework. *bioRxiv*. [PubMed](https://pubmed.ncbi.nlm.nih.gov/40027837) 5. **Matheson GJ**, Lundberg J, Gärde M, Veldman ER, Tateno A, Okubo Y, Tiger M & Ogden RT (2024). A Reference Tissue Implementation of Simultaneous Multifactor Bayesian Analysis (SiMBA) of PET Time Activity Curve Data. *bioRxiv*. [PubMed](https://pubmed.ncbi.nlm.nih.gov/39677746) 6. Galassi A, Norgaard M, Thomas AG, Gonzalez-Escamilla G, Svarer C, Rorden C, **Matheson GJ**, Knudsen GM, Innis RB, Ganz M, Eierud C, Bilgel M & Pernet C (2024). PET2BIDS: a library for converting Positron Emission Tomography data to BIDS. *J Open Source Softw*, *9*(100). [PubMed](https://pubmed.ncbi.nlm.nih.gov/39309688) 7. Gärde M, **Matheson GJ**, Varnäs K, Svenningsson P, Hedman-Lagerlöf E, Lundberg J, Farde L & Tiger M (2024). Altered Serotonin 1B Receptor Binding After Escitalopram for Depression Is Correlated With Treatment Effect. *Int J Neuropsychopharmacol*, *27*(5). [PubMed](https://pubmed.ncbi.nlm.nih.gov/38695786) 8. **Matheson GJ**, Zanderigo F, Miller JM, Bartlett EA, Mann JJ & Ogden RT (2024). PET Imaging of the Serotonin 1A Receptor in Major Depressive Disorder: Hierarchical Multivariate Analysis of [11C]WAY100635 Overcomes Outcome Measure Discrepancies. *bioRxiv*. [PubMed](https://pubmed.ncbi.nlm.nih.gov/38559101) 9. **Matheson GJ**, Ge L, Zhang M, Sun B, Tu Y, Zanderigo F, Forsberg Morèn A & Ogden RT (2023). Parametric and non-parametric Poisson regression for modelling of the arterial input function in positron emission tomography. *EJNMMI Phys*, *10*(1), 72. [PubMed](https://pubmed.ncbi.nlm.nih.gov/37987874) 10. Shieh D, **Matheson GJ** & Ogden RT (2023). Nonlinear Mixed-Effects Modeling Approach for Simplified Reference Tissue Model. *IEEE Trans Biomed Eng*, *71*(4), 1191-1196. [PubMed](https://pubmed.ncbi.nlm.nih.gov/37930902) 11. **Matheson GJ** & Ogden RT (2023). Multivariate analysis of PET pharmacokinetic parameters improves inferential efficiency. *EJNMMI Phys*, *10*(1), 17. [PubMed](https://pubmed.ncbi.nlm.nih.gov/36907944) 12. Jangard S, Jayaram-Lindström N, Isacsson NH, **Matheson GJ**, Plavén-Sigray P, Franck J, Borg J, Farde L & Cervenka S (2023). Striatal dopamine D2 receptor availability as a predictor of subsequent alcohol use in social drinkers. *Addiction*, *118*(6), 1053-1061. [PubMed](https://pubmed.ncbi.nlm.nih.gov/36710462) 13. Balter LJT, **Matheson GJ**, Sundelin T, Sterzer P, Petrovic P & Axelsson J (2022). Experimental Sleep Deprivation Results in Diminished Perceptual Stability Independently of Psychosis Proneness. *Brain Sci*, *12*(10). [PubMed](https://pubmed.ncbi.nlm.nih.gov/36291272) 14. Millischer V, **Matheson GJ**, Bergen SE, Coombes BJ, Ponzer K, Wikström F, Jagiello K, Lundberg M, Stenvinkel P, Biernacka JM, Breuer O, Martinsson L, Landén M, Backlund L, Lavebratt C & Schalling M (2022). Improving lithium dose prediction using population pharmacokinetics and pharmacogenomics: a cohort genome-wide association study in Sweden. *Lancet Psychiatry*, *9*(6), 447-457. [PubMed](https://pubmed.ncbi.nlm.nih.gov/35569502) 15. **Matheson GJ** & Ogden RT (2022). Simultaneous multifactor Bayesian analysis (SiMBA) of PET time activity curve data. *Neuroimage*, *256*, 119195. [PubMed](https://pubmed.ncbi.nlm.nih.gov/35452807) 16. Norgaard M, **Matheson GJ**, Hansen HD, Thomas A, Searle G, Rizzo G, Veronese M, Giacomel A, Yaqub M, Tonietto M, Funck T, Gillman A, Boniface H, Routier A, Dalenberg JR, Betthauser T, Feingold F, Markiewicz CJ, Gorgolewski KJ, Blair RW, Appelhoff S, Gau R, Salo T, Niso G, Pernet C, Phillips C, Oostenveld R, Gallezot JD, Carson RE, Knudsen GM, Innis RB & Ganz M (2022). PET-BIDS, an extension to the brain imaging data structure for positron emission tomography. *Sci Data*, *9*(1), 65. [PubMed](https://pubmed.ncbi.nlm.nih.gov/35236846) 17. Plavén-Sigray P, Ikonen Victorsson P, Santillo A, **Matheson GJ**, Lee M, Collste K, Fatouros-Bergman H, Sellgren CM, Erhardt S, Agartz I, Halldin C, Farde L & Cervenka S (2021). Thalamic dopamine D2-receptor availability in schizophrenia: a study on antipsychotic-naive patients with first-episode psychosis and a meta-analysis. *Mol Psychiatry*, *27*(2), 1233-1240. [PubMed](https://pubmed.ncbi.nlm.nih.gov/34759359) 18. Tiger M, Gärde M, Tateno A, **Matheson GJ**, Sakayori T, Nogami T, Moriya H, Varnäs K, Arakawa R & Okubo Y (2021). A positron emission tomography study of the serotonin1B receptor effect of electroconvulsive therapy for severe major depressive episodes. *J Affect Disord*, *294*, 645-651. [PubMed](https://pubmed.ncbi.nlm.nih.gov/34332365) 19. Bai W, Al-Karaghouli M, Stach J, Sung S, **Matheson GJ** & Abraldes JG (2021). Test-Retest Reliability and Consistency of HVPG and Impact on Trial Design: A Study in 289 Patients from 20 Randomized Controlled Trials. *Hepatology*, *74*(6), 3301-3315. [PubMed](https://pubmed.ncbi.nlm.nih.gov/34181770) 20. Freiburghaus T, Svensson JE, **Matheson GJ**, Plavén-Sigray P, Lundberg J, Farde L & Cervenka S (2020). Low convergent validity of [11C]raclopride binding in extrastriatal brain regions: A PET study of within-subject correlations with [11C]FLB 457. *Neuroimage*, *226*, 117523. [PubMed](https://pubmed.ncbi.nlm.nih.gov/33144221) 21. Kerstens VS, Fazio P, Sundgren M, **Matheson GJ**, Franzén E, Halldin C, Cervenka S, Svenningsson P & Varrone A (2020). Reliability of dopamine transporter PET measurements with [18F]FE-PE2I in patients with Parkinson's disease. *EJNMMI Res*, *10*(1), 95. [PubMed](https://pubmed.ncbi.nlm.nih.gov/32797307) 22. Plavén-Sigray P, **Matheson GJ**, Coughlin JM, Hafizi S, Laurikainen H, Ottoy J, De Picker L, Rusjan P, Hietala J, Howes OD, Mizrahi R, Morrens M, Pomper MG & Cervenka S (2020). Meta-analysis of the Glial Marker TSPO in Psychosis Revisited: Reconciling Inconclusive Findings of Patient-Control Differences. *Biol Psychiatry*, *89*(3), e5-e8. [PubMed](https://pubmed.ncbi.nlm.nih.gov/32682565) 23. Tjerkaski J, Cervenka S, Farde L & **Matheson GJ** (2020). Kinfitr - an open-source tool for reproducible PET modelling: validation and evaluation of test-retest reliability. *EJNMMI Res*, *10*(1), 77. [PubMed](https://pubmed.ncbi.nlm.nih.gov/32642865) 24. **Matheson GJ**, Plavén-Sigray P, Louzolo A, Borg J, Farde L, Petrovic P & Cervenka S (2020). Dopamine D1 receptor availability is not associated with delusional ideation measures of psychosis proneness. *Schizophr Res*, *222*, 175-184. [PubMed](https://pubmed.ncbi.nlm.nih.gov/32616361) 25. Knudsen GM, Ganz M, Appelhoff S, Boellaard R, Bormans G, Carson RE, Catana C, Doudet D, Gee AD, Greve DN, Gunn RN, Halldin C, Herscovitch P, Huang H, Keller SH, Lammertsma AA, Lanzenberger R, Liow JS, Lohith TG, Lubberink M, Lyoo CH, Mann JJ, **Matheson GJ**, Nichols TE, Nørgaard M, Ogden T, Parsey R, Pike VW, Price J, Rizzo G, Rosa-Neto P, Schain M, Scott PJ, Searle G, Slifstein M, Suhara T, Talbot PS, Thomas A, Veronese M, Wong DF, Yaqub M, Zanderigo F, Zoghbi S & Innis RB (2020). Guidelines for the content and format of PET brain data in publications and archives: A consensus paper. *J Cereb Blood Flow Metab*, *40*(8), 1576-1585. [PubMed](https://pubmed.ncbi.nlm.nih.gov/32065076) 26. Millischer V, **Matheson GJ**, Martinsson L, Römer Ek I, Schalling M, Lavebratt C & Backlund L (2019). AKT1 and genetic vulnerability to bipolar disorder. *Psychiatry Res*, *284*, 112677. [PubMed](https://pubmed.ncbi.nlm.nih.gov/31810747) 27. **Matheson GJ**, Plavén-Sigray P, Tuisku J, Rinne J, Matuskey D & Cervenka S (2019). Clinical brain PET research must embrace multi-centre collaboration and data sharing or risk its demise. *Eur J Nucl Med Mol Imaging*, *47*(2), 502-504. [PubMed](https://pubmed.ncbi.nlm.nih.gov/31713656) 28. **Matheson GJ** (2019). We need to talk about reliability: making better use of test-retest studies for study design and interpretation. *PeerJ*, *7*, e6918. [PubMed](https://pubmed.ncbi.nlm.nih.gov/31179173) 29. Stenkrona P, **Matheson GJ**, Halldin C, Cervenka S & Farde L (2019). D1-Dopamine Receptor Availability in First-Episode Neuroleptic Naive Psychosis Patients. *Int J Neuropsychopharmacol*, *22*(7), 415-425. [PubMed](https://pubmed.ncbi.nlm.nih.gov/30958880) 30. Caravaggio F, Plavén-Sigray P, **Matheson GJ**, Plitman E, Chakravarty MM, Borg J, Graff-Guerrero A & Cervenka S (2018). Trait impulsivity is not related to post-commissural putamen volumes: A replication study in healthy men. *PLoS One*, *13*(12), e0209584. [PubMed](https://pubmed.ncbi.nlm.nih.gov/30571791) 31. Plavén-Sigray P, **Matheson GJ**, Cselényi Z, Jucaite A, Farde L & Cervenka S (2018). Test-retest reliability and convergent validity of (R)-[11C]PK11195 outcome measures without arterial input function. *EJNMMI Res*, *8*(1), 102. [PubMed](https://pubmed.ncbi.nlm.nih.gov/30498919) 32. Griffioen G, **Matheson GJ**, Cervenka S, Farde L & Borg J (2018). Serotonin 5-HT1A receptor binding and self-transcendence in healthy control subjects-a replication study using Bayesian hypothesis testing. *PeerJ*, *6*, e5790. [PubMed](https://pubmed.ncbi.nlm.nih.gov/30479884) 33. Stenkrona P, **Matheson GJ**, Cervenka S, Sigray PP, Halldin C & Farde L (2018). [11C]SCH23390 binding to the D1-dopamine receptor in the human brain-a comparison of manual and automated methods for image analysis. *EJNMMI Res*, *8*(1), 74. [PubMed](https://pubmed.ncbi.nlm.nih.gov/30069645) 34. Plavén-Sigray P, **Matheson GJ**, Collste K, Ashok AH, Coughlin JM, Howes OD, Mizrahi R, Pomper MG, Rusjan P, Veronese M, Wang Y & Cervenka S (2018). Positron Emission Tomography Studies of the Glial Cell Marker Translocator Protein in Patients With Psychosis: A Meta-analysis Using Individual Participant Data. *Biol Psychiatry*, *84*(6), 433-442. [PubMed](https://pubmed.ncbi.nlm.nih.gov/29653835) 35. Plavén-Sigray P, **Matheson GJ**, Gustavsson P, Stenkrona P, Halldin C, Farde L & Cervenka S (2018). Is dopamine D1 receptor availability related to social behavior? A positron emission tomography replication study. *PLoS One*, *13*(3), e0193770. [PubMed](https://pubmed.ncbi.nlm.nih.gov/29543812) 36. Plavén-Sigray P, **Matheson GJ**, Schiffler BC & Thompson WH (2017). The readability of scientific texts is decreasing over time. *Elife*, *6*. [PubMed](https://pubmed.ncbi.nlm.nih.gov/28873054) 37. **Matheson GJ**, Plavén-Sigray P, Forsberg A, Varrone A, Farde L & Cervenka S (2017). Assessment of simplified ratio-based approaches for quantification of PET [11C]PBR28 data. *EJNMMI Res*, *7*(1), 58. [PubMed](https://pubmed.ncbi.nlm.nih.gov/28733954) 38. **Matheson GJ**, Stenkrona P, Cselényi Z, Plavén-Sigray P, Halldin C, Farde L & Cervenka S (2017). Reliability of volumetric and surface-based normalisation and smoothing techniques for PET analysis of the cortex: A test-retest analysis using [11C]SCH-23390. *Neuroimage*, *155*, 344-353. [PubMed](https://pubmed.ncbi.nlm.nih.gov/28419852) 39. Plavén-Sigray P, Hedman E, Victorsson P, **Matheson GJ**, Forsberg A, Djurfeldt DR, Rück C, Halldin C, Lindefors N & Cervenka S (2017). Extrastriatal dopamine D2-receptor availability in social anxiety disorder. *Eur Neuropsychopharmacol*, *27*(5), 462-469. [PubMed](https://pubmed.ncbi.nlm.nih.gov/28377075) 40. Borg J, Cervenka S, Kuja-Halkola R, **Matheson GJ**, Jönsson EG, Lichtenstein P, Henningsson S, Ichimiya T, Larsson H, Stenkrona P, Halldin C & Farde L (2016). Contribution of non-genetic factors to dopamine and serotonin receptor availability in the adult human brain. *Mol Psychiatry*, *21*(8), 1077-84. [PubMed](https://pubmed.ncbi.nlm.nih.gov/26821979) 41. **Matheson GJ**, Schain M, Almeida R, Lundberg J, Cselényi Z, Borg J, Varrone A, Farde L & Cervenka S (2015). Diurnal and seasonal variation of the brain serotonin system in healthy male subjects. *Neuroimage*, *112*, 225-231. [PubMed](https://pubmed.ncbi.nlm.nih.gov/25772667)